Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1986 3
1987 4
1988 1
1989 1
1990 4
1991 3
1992 5
1993 1
1994 1
1995 2
2000 1
2001 1
2002 1
2003 1
2005 3
2007 1
2010 2
2011 1
2013 1
2014 2
2015 3
2016 2
2018 2
2019 3
2020 2
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A, Segatto O, Stenzinger A, Saborowski A. Vogel A, et al. Among authors: segatto o. Annu Rev Med. 2023 Jan 27;74:293-306. doi: 10.1146/annurev-med-042921-024707. Epub 2022 Sep 28. Annu Rev Med. 2023. PMID: 36170665 Free article. Review.
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, Carpino G, Goeppert B, Roessler S, Kendall TJ, Evert M, Gonzalez-Sanchez E, Valle JW, Vogel A, Bridgewater J, Borad MJ, Gores GJ, Roberts LR, Marin JJG, Andersen JB, Alvaro D, Forner A, Banales JM, Cardinale V, Macias RIR, Vicent S, Chen X, Braconi C, Verstegen MMA, Fouassier L; CCA Model Consortium. Calvisi DF, et al. Among authors: segatto o. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):462-480. doi: 10.1038/s41575-022-00739-y. Epub 2023 Feb 8. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36755084 Free article. Review.
Current and novel therapeutic opportunities for systemic therapy in biliary cancer.
Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Marin JJG, et al. Among authors: segatto o. Br J Cancer. 2020 Sep;123(7):1047-1059. doi: 10.1038/s41416-020-0987-3. Epub 2020 Jul 22. Br J Cancer. 2020. PMID: 32694694 Free PMC article. Review.
FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G, Porru M, Lamberti D, Buglioni S, Rollo F, Amoreo CA, Manni I, Giannarelli D, Cristofoletti C, Russo G, Borad MJ, Grazi GL, Diodoro MG, Giordano S, Sacconi A, Forcato M, Anastasi S, Leonetti C, Segatto O. Cristinziano G, et al. Among authors: segatto o. J Hepatol. 2021 Aug;75(2):351-362. doi: 10.1016/j.jhep.2021.02.032. Epub 2021 Mar 17. J Hepatol. 2021. PMID: 33741397
Negative regulation of receptor tyrosine kinase signals.
Fiorini M, Alimandi M, Fiorentino L, Sala G, Segatto O. Fiorini M, et al. Among authors: segatto o. FEBS Lett. 2001 Feb 16;490(3):132-41. doi: 10.1016/s0014-5793(01)02116-0. FEBS Lett. 2001. PMID: 11223028 Free article. Review.
56 results